AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...

Related Keywords

Puerto Rico ,Saudi Arabia ,Brazil ,United States ,Japan ,Milano ,Lombardia ,Italy ,Australia ,Canada ,United Kingdom ,Great Britain ,America ,Kingdom Of Saudi Arabia ,Jay Bradner ,Madison Howard ,Mario Salvi ,Justin Claeys ,Jessica Akopyan ,European Medicines Agency ,Therapeutic Goods Administration ,Youtube ,Ministry Of Health ,Graves Orbitopathy Center Aldo ,Fast Company ,Teneobio Inc ,Amgen ,Beigene Ltd ,Exchange Commission ,Health Canada ,World Most Innovative Companies ,European Group On Grave Orbitopathy ,European Union ,Linkedin ,Visa ,Instagram ,Kyowa Kirin Co Ltd ,Regulatory Agency ,Chemocentryx Inc ,Marketing Authorization Application ,Thyroid Eye Disease ,New Drug Submission ,Inflammatory Bowel Disease ,Impairment Including Hearing Loss ,Full Prescribing Information ,Most Innovative ,Best Large ,Dow Jones Industrial ,Nasdaq Stock Market ,Horizon Therapeutics ,Patients With Thyroid Eye Disease ,Long Duration ,Slow Disease ,Clinical Endocrinology ,Thyroid Associated ,Grave Disease Is Mediated Through ,Insulin Like Growth Factor ,European Group ,Grave Orbitopathy ,Clinical Practice Guidelines ,Medical Management ,